Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 8, 2019. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Exercise and Sale of Stock Options |
| Instrument | American Depositary Shares (ADSs) |
| Total Volume | 4,600 ADSs |
| Exercise Price | $33.42 per ADS |
| Sale Price | $41.08 per ADS |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine equity compensation event involving Mr. N Hirons, SVP of Global Ethics & Compliance.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of a transaction executed on February 7, 2019, on the New York Stock Exchange.
Key Facts for Investor Verification
- The transaction involved the exercise of options granted on February 17, 2009.
- Mr. N Hirons exercised options for 4,600 ADSs at $33.42 and immediately sold them at $41.08.
- The sale generated a realized gain of $7.66 per share for the executive.
- This filing does not contain quarterly or annual financial performance data.